Table 1.
Patient demographics, diseases, and medications
| HFpEF | Control | P | |
|---|---|---|---|
| n (%) | 6 | 9 | |
| Male | 3 (50) | 4 (44) | 1.00 |
| Age (years) | 53 ± 19 | 62 ± 4 | 0.32 |
| Body weight (kg) | 86 ± 21 | 87 ± 20 | 0.97 |
| BMI (kg/m2) | 30 ± 5 | 31 ± 6 | 0.67 |
| Systolic Blood Pressure (mmHg) | 135 ± 28 | 138 ± 15 | 0.82 |
| Diastolic Blood Pressure (mmHg) | 79 ± 11 | 72 ± 13 | 0.31 |
| Ejection Fraction (%) | 57 ± 9 | 63 ± 8 | 0.20 |
| Serum glucose (mg/dL) | 136 ± 63 | 101 ± 37 | 0.30 |
| Underlying disease, n (%) | |||
| Heart failure | 6 (100) | 0 (0) | 0.0002* |
| Type 2 diabetes | 2 (33) | 4 (44) | 1.00 |
| Hypertension | 6 (100) | 9 (100) | 1.00 |
| Hyperlipidemia | 4 (67) | 5 (56) | 1.00 |
| Coronary artery disease | 4 (67) | 8 (89) | 0.53 |
| Peripheral vascular disease | 1 (17) | 1 (11) | 1.00 |
| COPD | 1 (17) | 2 (22) | 1.00 |
| Medications, n (%) | |||
| Aspirin | 3 (50) | 7 (78) | 0.33 |
| Lipid lowering | 5 (83) | 7 (78) | 1.00 |
| Insulin | 1(17) | 0 (0) | 0.40 |
| Oral antidiabetic | 1(17) | 2 (22) | 1.00 |
| Beta blocker | 4 (67) | 6 (67) | 1.00 |
| ACE inhibitor | 4 (67) | 4 (44) | 0.61 |
| Diuretic | 4 (67) | 4 (44) | 1.00 |
| Anticoagulant | 3 (50) | 4 (44) | 1.00 |
| Calcium channel blocker | 1 (17) | 1 (11) | 1.00 |
| Surgical procedure, n (%) | |||
| CABG | 4 (67) | 8 (89) | 0.53 |
| Valve replacement | 2 (33) | 2 (22) | 1.00 |
n, number of HFpEF and control patients studied, categorical variables also indicate percentages. For continues variables mean ± SD are shown.
*
indicates statistical difference. All categorical variables were examined by Fisher’s exact test and continuous variables were assessed by Student’s t-test between the two patient groups. BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting.